News
![1 Reason I Wouldn't Buy This High-Yielding Dividend Stock: https://g.foolcdn.com/editorial/images/739959/a-person-sitting-with-their-child-looking-at-a-laptop.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNmRWYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1a124f1327508ee120a78c6e9727b9c955f2fa26/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-person-sitting-with-their-child-looking-at-a-laptop.jpg?locale=us)
1 Reason I Wouldn't Buy This High-Yielding Dividend Stock
A high-yielding dividend stock can generate lots of dividend income for your portfolio. But that doesn't mean you should buy a stock only because of its yield. Dividends are never guaranteed and
![Better Pharma Buy: Viatris vs. Pfizer: https://g.foolcdn.com/editorial/images/740301/gettyimages-women-investors.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMWhVYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--220344efdf8471a866d4b2c39040e96be82153cb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-women-investors.jpg?locale=us)
Better Pharma Buy: Viatris vs. Pfizer
Pfizer (NYSE: PFE) and Viatris (NASDAQ: VTRS) have a common past. That's because Viatris came about a few years ago when Pfizer's Upjohn business merged with generic drug giant, Mylan. Since, their
![Better Pharma Buy: Viatris vs. Pfizer: https://g.foolcdn.com/editorial/images/740301/gettyimages-women-investors.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMWhVYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--220344efdf8471a866d4b2c39040e96be82153cb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-women-investors.jpg?locale=us)
Better Pharma Buy: Viatris vs. Pfizer
Pfizer (NYSE: PFE) and Viatris (NASDAQ: VTRS) have a common past. That's because Viatris came about a few years ago when Pfizer's Upjohn business merged with generic drug giant, Mylan. Since, their
![Why Amarin Stock Is Sinking Today: https://g.foolcdn.com/editorial/images/740399/downsizing.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBenBVYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dd31d81f494a5c3414c0903e1d69d3364b3746d0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/downsizing.jpg?locale=us)
Why Amarin Stock Is Sinking Today
Shares of Amarin (NASDAQ: AMRN) were sinking 22.7% as of 10:56 a.m. ET on Wednesday. The steep decline came after the drugmaker announced an organizational restructuring after the market close on
![Better High-Yield Dividend Stock: Altria or Viatris?: https://g.foolcdn.com/editorial/images/739969/dividends.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOUJQYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7a6cad1dba0bfeeeda7221d75d3ba22dc4bd3e6d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/dividends.jpg?locale=us)
Better High-Yield Dividend Stock: Altria or Viatris?
If you are looking for a high-yield dividend stock to boost your income, you might be interested in Altria (NYSE: MO) or Viatris (NASDAQ: VTRS). Both companies offer attractive dividend yields of
![Better High-Yield Dividend Stock: Altria or Viatris?: https://g.foolcdn.com/editorial/images/739969/dividends.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOUJQYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7a6cad1dba0bfeeeda7221d75d3ba22dc4bd3e6d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/dividends.jpg?locale=us)
Better High-Yield Dividend Stock: Altria or Viatris?
If you are looking for a high-yield dividend stock to boost your income, you might be interested in Altria (NYSE: MO) or Viatris (NASDAQ: VTRS). Both companies offer attractive dividend yields of
![3 Reasons to Buy Viatris Stock, and 1 Reason to Sell: https://g.foolcdn.com/editorial/images/739304/team-of-medical-experts-talking-on-a-meeting-at-doctors-office.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFJPYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--64c0d096bbc55372efdbb7ed21e4c1a67d4ff592/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/team-of-medical-experts-talking-on-a-meeting-at-doctors-office.jpg?locale=us)
3 Reasons to Buy Viatris Stock, and 1 Reason to Sell
Buying shares of a generic drug manufacturer like Viatris (NASDAQ: VTRS) isn't the right move for everyone. While most investors would look for such companies to have a long history of bulletproof
![3 Reasons to Buy Viatris Stock, and 1 Reason to Sell: https://g.foolcdn.com/editorial/images/739304/team-of-medical-experts-talking-on-a-meeting-at-doctors-office.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFJPYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--64c0d096bbc55372efdbb7ed21e4c1a67d4ff592/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/team-of-medical-experts-talking-on-a-meeting-at-doctors-office.jpg?locale=us)
3 Reasons to Buy Viatris Stock, and 1 Reason to Sell
Buying shares of a generic drug manufacturer like Viatris (NASDAQ: VTRS) isn't the right move for everyone. While most investors would look for such companies to have a long history of bulletproof
![Wall Street Thinks Viatris Stock Will Rise 25% -- Could It Grow Even More?: https://g.foolcdn.com/editorial/images/738452/investor-stands-in-kitchen-considering-laptop.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzVEYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0aedf0460c35e4cdaced95c51ab3488c4ee294e5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-stands-in-kitchen-considering-laptop.jpg?locale=us)
Wall Street Thinks Viatris Stock Will Rise 25% -- Could It Grow Even More?
For a generic drugmaker like Viatris (NASDAQ: VTRS), big spurts of growth are unlikely. The market for low-cost generic medications is competitive, and success is largely defined by maintaining
![Wall Street Thinks Viatris Stock Will Rise 25% -- Could It Grow Even More?: https://g.foolcdn.com/editorial/images/738452/investor-stands-in-kitchen-considering-laptop.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzVEYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0aedf0460c35e4cdaced95c51ab3488c4ee294e5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-stands-in-kitchen-considering-laptop.jpg?locale=us)
Wall Street Thinks Viatris Stock Will Rise 25% -- Could It Grow Even More?
For a generic drugmaker like Viatris (NASDAQ: VTRS), big spurts of growth are unlikely. The market for low-cost generic medications is competitive, and success is largely defined by maintaining
![These 2 Dividend Stocks Yield 5% -- and They Aren't Risky Buys: https://g.foolcdn.com/editorial/images/735027/a-couple-reviewing-a-statement.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN2NwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--103827aa67bdf4171dd1e1b391816c7491f5b037/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-couple-reviewing-a-statement.jpg?locale=us)
These 2 Dividend Stocks Yield 5% -- and They Aren't Risky Buys
You can secure a 5% dividend yield without being too risky or aggressive. Sometimes, it's a matter of jumping on a good opportunity when it arises. A stock can fall in value for various reasons
![These 2 Dividend Stocks Yield 5% -- and They Aren't Risky Buys: https://g.foolcdn.com/editorial/images/735027/a-couple-reviewing-a-statement.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN2NwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--103827aa67bdf4171dd1e1b391816c7491f5b037/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-couple-reviewing-a-statement.jpg?locale=us)
These 2 Dividend Stocks Yield 5% -- and They Aren't Risky Buys
You can secure a 5% dividend yield without being too risky or aggressive. Sometimes, it's a matter of jumping on a good opportunity when it arises. A stock can fall in value for various reasons
![It's Cheap and Pays a Big Dividend, But Is Viatris Stock a Buy?: https://g.foolcdn.com/editorial/images/732730/three-investors-meet-with-paperwork.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBODhSYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--05bb944f2d886fae0c18acf9ef5620c14c4bbd9c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/three-investors-meet-with-paperwork.jpg?locale=us)
It's Cheap and Pays a Big Dividend, But Is Viatris Stock a Buy?
Companies that produce generic drugs aren't known for being exciting investments, and there's little chance they'll ever expand as fast as your average tech stock or most other growth stocks. If
![It's Cheap and Pays a Big Dividend, But Is Viatris Stock a Buy?: https://g.foolcdn.com/editorial/images/732730/three-investors-meet-with-paperwork.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBODhSYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--05bb944f2d886fae0c18acf9ef5620c14c4bbd9c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/three-investors-meet-with-paperwork.jpg?locale=us)
It's Cheap and Pays a Big Dividend, But Is Viatris Stock a Buy?
Companies that produce generic drugs aren't known for being exciting investments, and there's little chance they'll ever expand as fast as your average tech stock or most other growth stocks. If
![Amarin Plc (AMRN) Q1 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=us)
Amarin Plc (AMRN) Q1 2023 Earnings Call Transcript
Image source: The Motley Fool.
Amarin Plc (NASDAQ: AMRN)Q1 2023 Earnings CallMay 03, 2023, 8:00 a.m. ET
Operator
Source Fool.com
![Why Shares of Adaptimmune Therapeutics Jumped Tuesday: https://g.foolcdn.com/editorial/images/727860/dna-genetic-sequencing-biotech-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeG5zYWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--280ffaebd19399c2465b1009a297637f5dc516f9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/dna-genetic-sequencing-biotech-1.jpg?locale=us)
Why Shares of Adaptimmune Therapeutics Jumped Tuesday
Shares of Adaptimmune Therapeutics (NASDAQ: ADAP) were up as much as 9.7% early Tuesday after the clinical-stage biotech announced that it had reached an agreement with GSK (NYSE: GSK) to return the
![LivaNova erhält 510(k)-Freigabe der US-amerikanischen FDA für Essenz-Herz-Lungen-Maschine für kardiopulmonale Bypassverfahren: https://mms.businesswire.com/media/20230309005788/de/1735168/5/Essenz_DMcDonald_Milano_2023_03_02-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNUwyV1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d3640e0e23ee1de70910e104557ad9d046d97be9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Essenz_DMcDonald_Milano_2023_03_02-12.jpg?locale=us)
LivaNova erhält 510(k)-Freigabe der US-amerikanischen FDA für Essenz-Herz-Lungen-Maschine für kardiopulmonale Bypassverfahren
LivaNova PLC (Nasdaq: LIVN), ein marktführendes Unternehmen im Bereich medizintechnische Innovationen, gab heute bekannt, dass es die 510(k)-Freigabe von der US-amerikanischen Food and Drug
![LivaNova Receives U.S. FDA 510(k) Clearance for Essenz Heart-Lung Machine for Cardiopulmonary Bypass Procedures: https://mms.businesswire.com/media/20230309005787/en/1735168/5/Essenz_DMcDonald_Milano_2023_03_02-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMW4yV1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--939b864835fe30e2dfacce2fd2b909c9ba30b0a8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Essenz_DMcDonald_Milano_2023_03_02-12.jpg?locale=us)
LivaNova Receives U.S. FDA 510(k) Clearance for Essenz Heart-Lung Machine for Cardiopulmonary Bypass Procedures
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Essenz™
![LivaNova leitet die begrenzte Markteinführung des Essenz Perfusion System für kardiopulmonale Bypassverfahren in Europa ein: https://mms.businesswire.com/media/20230208005128/de/1707624/5/LIVN_Essenz_OR_team_2_CAPTION-One_of_the_first_clinical_cases_with_Essenz_at_San_Donato_Hospital%2C_Italy.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTdRV1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--60dd07967a832c1e75cb6ec1da5d6b4f90c98ca2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/LIVN_Essenz_OR_team_2_CAPTION-One_of_the_first_clinical_cases_with_Essenz_at_San_Donato_Hospital-2C_Italy.jpg?locale=us)
LivaNova leitet die begrenzte Markteinführung des Essenz Perfusion System für kardiopulmonale Bypassverfahren in Europa ein
LivaNova PLC (Nasdaq: LIVN), ein marktführendes Unternehmen im Bereich Medizintechnik und Innovation, hat heute den Beginn einer begrenzten kommerziellen Freigabe für das Essenz™ Perfusion System*
![LivaNova Initiates Limited Commercial Release in Europe of the Essenz Perfusion System for Cardiopulmonary Bypass Procedures: https://mms.businesswire.com/media/20230208005127/en/1707624/5/LIVN_Essenz_OR_team_2_CAPTION-One_of_the_first_clinical_cases_with_Essenz_at_San_Donato_Hospital%2C_Italy.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNWpRV1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d44e1bb057748a6d1765d7411245c0f4c180fe75/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/LIVN_Essenz_OR_team_2_CAPTION-One_of_the_first_clinical_cases_with_Essenz_at_San_Donato_Hospital-2C_Italy.jpg?locale=us)
LivaNova Initiates Limited Commercial Release in Europe of the Essenz Perfusion System for Cardiopulmonary Bypass Procedures
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the start of a limited commercial release for the Essenz™ Perfusion System*. The release has
![LivaNova Launches SenTiva DUO: https://mms.businesswire.com/media/20230131005958/en/1701271/5/SenTiva_Duo_Updated_B.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeG5LV1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--aed35eda78a90265cae60a7a5e084484a1991c66/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/SenTiva_Duo_Updated_B.jpg?locale=us)
LivaNova Launches SenTiva DUO
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today launched SenTiva DUO™, an implantable pulse generator (IPG) with a dual-pin header to provide VNS
![Alacer Corp. Launches New Eco-Conscious Toothpaste Brand Natean®](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Alacer Corp. Launches New Eco-Conscious Toothpaste Brand Natean®
Alacer Corp. today announced the launch of Natean®, a new eco-conscious oral healthcare brand providing products to consumers looking for nature-inspired toothpastes that deliver essential oral
![Alacer Corp. Launches New Eco-Conscious Toothpaste Brand Natean®](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Alacer Corp. Launches New Eco-Conscious Toothpaste Brand Natean®
Alacer Corp. today announced the launch of Natean®, a new eco-conscious oral healthcare brand providing products to consumers looking for nature-inspired toothpastes that deliver essential oral
![Astra Zeneca: Wirbel um COVID-19-Impfstoff](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Astra Zeneca: Wirbel um COVID-19-Impfstoff
AstraZeneca (WKN: 886455) teilte am Montag mit, dass die Nebenwirkungen seines potenziellen Corona-Impfstoffs bei älteren Menschen geringer seien. Die Wirkstoff-Hoffnung des britischen Pharmariesen
![Astra Zeneca: Wirbel um COVID-19-Impfstoff](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Astra Zeneca: Wirbel um COVID-19-Impfstoff
AstraZeneca (WKN: 886455) teilte am Montag mit, dass die Nebenwirkungen seines potenziellen Corona-Impfstoffs bei älteren Menschen geringer seien. Die Wirkstoff-Hoffnung des britischen Pharmariesen